Inari Medical to Present at the Canaccord Genuity 41st Annual Growth Conference
July 29 2021 - 4:01PM
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage
medical device company focused on developing products to treat and
transform the lives of patients suffering from venous diseases,
announced today that its management team will present at the
Canaccord Genuity 41st Annual Growth Conference on Thursday, August
12, 2021 at 10:30 a.m. Eastern Time.
About Inari Medical, Inc.Inari Medical, Inc. is
a commercial-stage medical device company focused on developing
products to treat and transform the lives of patients suffering
from venous diseases. Inari has developed two minimally-invasive,
novel catheter-based mechanical thrombectomy devices that are
designed to remove large clots from large vessels and eliminate the
need for thrombolytic drugs. The company purpose-built its products
for the specific characteristics of the venous system and the
treatment of the two distinct manifestations of venous
thromboembolism, or VTE: deep vein thrombosis and pulmonary
embolism. The ClotTriever system is 510(k)-cleared by the FDA and
CE Mark approved for the treatment of deep vein thrombosis. The
FlowTriever system is 510(k)-cleared by the FDA and CE Mark
approved for the treatment of pulmonary embolism and clot in
transit in the right atrium.
Investor Contact:Westwicke PartnersCaroline
CornerPhone +1-415-202-5678 caroline.corner@westwicke.com
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Apr 2023 to Apr 2024